RegenETP Management

Management criteria checks 2/4

RegenETP's CEO is Richard Hague, appointed in Apr 2020, has a tenure of 4.58 years. directly owns 0.62% of the company’s shares, worth $4.94K. The average tenure of the management team and the board of directors is 5.5 years and 7.4 years respectively.

Key information

Richard Hague

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.6yrs
CEO ownership	0.6%
Management average tenure	5.5yrs
Board average tenure	7.4yrs

Recent management updates

Recent updates

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

May 10

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Feb 19

PolarityTE to raise up to $10M with at-the-market offering

Jan 12

PolarityTE under pressure on pricing $8M registered direct offering

Dec 22

PolarityTE perks up after securing first U.S. patent

Nov 30

PolarityTE EPS beats by $0.02, beats on revenue

Nov 09

CEO Compensation Analysis

How has Richard Hague's remuneration changed compared to RegenETP's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$480k	US$449k	-US$8m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$1m	US$359k	-US$30m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$38m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$996k	US$358k	-US$43m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$2m	US$273k	-US$92m

Compensation vs Market: Insufficient data to establish whether Richard's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.

CEO

Richard Hague (64 yo)

4.6yrs

Tenure

US$479,808

Compensation

Mr. Richard Hague is Director of Remedium Bio, Inc since 2022. He serves as President at PolarityTE, Inc. since August 2019 and its Chief Executive Officer since August 2021 and also served as its Chief Op...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard Hague	President	4.6yrs	US$479.81k	0.62% $ 4.9k
Nikolai Sopko	Chief Scientific Officer and VP of R&D	6.3yrs	no data	no data
Rich Haerle	Vice President of Investor Relations & Strategy	6.5yrs	no data	no data
Mark Lehman	Chief Legal Officer	no data	no data	no data
Angela Ziegler	Vice President of Marketing & Public Relations	no data	no data	no data
Alain Adam	Vice President of Sales	6.3yrs	no data	no data
Jon Anthony Burrows	Senior VP of Corporate Development & President of Contract Services	no data	no data	no data
Ryan Mathis	Chief Medical Officer	3.2yrs	no data	no data
Kolby Day	Senior Vice President of Manufacturing Operations	2yrs	no data	no data

5.5yrs

Average Tenure

Experienced Management: RGTP.Q's management team is seasoned and experienced (5.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Hague	President	1.3yrs	US$479.81k	0.62% $ 4.9k
Michael Callahan	Member of Clinical Advisory board	no data	no data	no data
Stephen Milner	Member of Clinical Advisory Board	7.9yrs	no data	no data
Michael Grant	Member of Clinical Advisory Board	7.9yrs	no data	no data
Anand Kumar	Member of Clinical Advisory Board	7.9yrs	no data	no data
Anthony Tufaro	Member of Clinical Advisory Board	no data	no data	no data
Trinity Bivalacqua	Member of Clinical Advisory Board	no data	no data	no data
Shannath Merbs	Member of Clinical Advisory Board	no data	no data	no data
Ryan Katz	Member of Clinical Advisory Board	no data	no data	no data
Martin Robson	Member of Clinical Advisory Board	7.4yrs	no data	no data
William Hickerson	Member of Clinical Advisory Board	7.4yrs	no data	no data
Jeffrey Shupp	Member of Clinical Advisory Board	7.4yrs	no data	no data

7.4yrs

Average Tenure

Experienced Board: RGTP.Q's board of directors are considered experienced (7.4 years average tenure).

RegenETP Management

Management criteria checks 2/4

Key information

Recent management updates

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Independent Chairman of the Board recently bought US$259k worth of stock

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

New major risk - Share price stability

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$1.25

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Consensus revenue estimates fall by 40%

Price target decreased to US$15.38

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PolarityTE down 10% on lower-than-expected Q2 revenue

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

Price target decreased to US$15.38

First quarter 2022 earnings: Revenues miss analyst expectations

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$1.08

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

Consensus forecasts updated

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

PolarityTE Is Not A DeFi Coin

Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?

Independent Chairman of the Board recently bought US$259k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Analysts update estimates

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: US$1.54

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

PolarityTE to raise up to $10M with at-the-market offering

New 90-day high: US$1.32

PolarityTE under pressure on pricing $8M registered direct offering

New 90-day low: US$0.63

PolarityTE perks up after securing first U.S. patent

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.18 loss per share

New 90-day low: US$0.81